Diagnostic technologies for neuroblastoma
Diagnostic technologies for neuroblastoma
Neuroblastoma is an aggressive childhood cancer characterised by high relapse rates and heterogenicity. Current medical diagnostic methods involve an array of techniques, from blood tests to tumour biopsies. This process is associated with long-term physical and psychological trauma. Moreover, current technologies do not identify neuroblastoma at an early stage while tumours are easily resectable. In recent decades, many advancements have been made for neuroblastoma diagnosis, including liquid biopsy platforms, radiomics, artificial intelligence (AI) integration and biosensor technologies. These innovations support the trend towards rapid, non-invasive and cost-effective diagnostic methods which can be utilised for accurate risk stratification. Point-of-care (POC) diagnostic devices enable rapid and accurate detection of disease biomarkers and can be performed at the location of the patient. Whilst POC diagnostics has been well-researched within the oncological landscape, few devices have been reported for neuroblastoma, and these remain in the early research phase and as such are limited by lack of clinical validation. Recent research has revealed several potential biomarkers which have great translational potential for POC diagnosis, including proteomic, metabolic and epigenetic markers such as MYCN amplification and microRNAs (miRNAs). Using POC devices to detect high-risk biomarkers in biofluids such as blood and urine, offers a non-invasive approach to diagnosis of neuroblastoma, enabling early screening at a population level as well as real-time health monitoring at home. This is critical to mitigating long-term morbidity associated with late diagnosis and unnecessary treatment, in turn improving outcomes for neuroblastoma patients.
3630-3664
Khelifa, Leena
1606ef7a-eb4c-4921-acf5-175a5e540891
Hu, Yubing
d9656e21-7f7c-451e-9a4b-83b0ccba04fc
Tall, Jennifer
379a737a-07a9-49f8-9e3f-c59ebb622744
Khelifa, Rasha
7c44b49d-763f-4177-b69a-1e82bce5c36d
Ali, Amina
919cb9d5-593f-463e-abd5-c45ab30d809b
Poon, Evon
e534b341-fd36-445f-9186-c4384b1fa98c
Khelifa, Mohamed Zaki
666f9dcb-8469-4f90-ad16-505eff6289ce
Yang, Guowei
19a7c9d7-3e16-4b88-9f1f-3905be559b8e
Jones, Catarina
47292d23-693e-4d91-b4c3-4d533e6b3070
Moreddu, Rosalia
8a5d77bc-dac4-4966-baa3-be26c5eec1ef
Jiang, Nan
459b43f7-3bb4-4e31-87ae-bf40248d6acb
Tasoglu, Savas
558202bd-9e05-4e80-9573-2d206e96c817
Chesler, Louis
1cffa023-1454-48ef-9b75-abaaeda6358d
Yetisen, Ali K.
3740f5f5-f13a-4bba-b91a-3c753bed0b18
14 July 2025
Khelifa, Leena
1606ef7a-eb4c-4921-acf5-175a5e540891
Hu, Yubing
d9656e21-7f7c-451e-9a4b-83b0ccba04fc
Tall, Jennifer
379a737a-07a9-49f8-9e3f-c59ebb622744
Khelifa, Rasha
7c44b49d-763f-4177-b69a-1e82bce5c36d
Ali, Amina
919cb9d5-593f-463e-abd5-c45ab30d809b
Poon, Evon
e534b341-fd36-445f-9186-c4384b1fa98c
Khelifa, Mohamed Zaki
666f9dcb-8469-4f90-ad16-505eff6289ce
Yang, Guowei
19a7c9d7-3e16-4b88-9f1f-3905be559b8e
Jones, Catarina
47292d23-693e-4d91-b4c3-4d533e6b3070
Moreddu, Rosalia
8a5d77bc-dac4-4966-baa3-be26c5eec1ef
Jiang, Nan
459b43f7-3bb4-4e31-87ae-bf40248d6acb
Tasoglu, Savas
558202bd-9e05-4e80-9573-2d206e96c817
Chesler, Louis
1cffa023-1454-48ef-9b75-abaaeda6358d
Yetisen, Ali K.
3740f5f5-f13a-4bba-b91a-3c753bed0b18
Khelifa, Leena, Hu, Yubing, Tall, Jennifer, Khelifa, Rasha, Ali, Amina, Poon, Evon, Khelifa, Mohamed Zaki, Yang, Guowei, Jones, Catarina, Moreddu, Rosalia, Jiang, Nan, Tasoglu, Savas, Chesler, Louis and Yetisen, Ali K.
(2025)
Diagnostic technologies for neuroblastoma.
Lab on a Chip, 25 (15), .
(doi:10.1039/D4LC00005F).
Abstract
Neuroblastoma is an aggressive childhood cancer characterised by high relapse rates and heterogenicity. Current medical diagnostic methods involve an array of techniques, from blood tests to tumour biopsies. This process is associated with long-term physical and psychological trauma. Moreover, current technologies do not identify neuroblastoma at an early stage while tumours are easily resectable. In recent decades, many advancements have been made for neuroblastoma diagnosis, including liquid biopsy platforms, radiomics, artificial intelligence (AI) integration and biosensor technologies. These innovations support the trend towards rapid, non-invasive and cost-effective diagnostic methods which can be utilised for accurate risk stratification. Point-of-care (POC) diagnostic devices enable rapid and accurate detection of disease biomarkers and can be performed at the location of the patient. Whilst POC diagnostics has been well-researched within the oncological landscape, few devices have been reported for neuroblastoma, and these remain in the early research phase and as such are limited by lack of clinical validation. Recent research has revealed several potential biomarkers which have great translational potential for POC diagnosis, including proteomic, metabolic and epigenetic markers such as MYCN amplification and microRNAs (miRNAs). Using POC devices to detect high-risk biomarkers in biofluids such as blood and urine, offers a non-invasive approach to diagnosis of neuroblastoma, enabling early screening at a population level as well as real-time health monitoring at home. This is critical to mitigating long-term morbidity associated with late diagnosis and unnecessary treatment, in turn improving outcomes for neuroblastoma patients.
Text
d4lc00005f
- Version of Record
More information
Accepted/In Press date: 13 June 2025
Published date: 14 July 2025
Identifiers
Local EPrints ID: 504602
URI: http://eprints.soton.ac.uk/id/eprint/504602
ISSN: 1473-0197
PURE UUID: d07de11b-ce67-45ab-8f95-f2bfd103e59a
Catalogue record
Date deposited: 16 Sep 2025 16:48
Last modified: 17 Sep 2025 02:20
Export record
Altmetrics
Contributors
Author:
Leena Khelifa
Author:
Yubing Hu
Author:
Jennifer Tall
Author:
Rasha Khelifa
Author:
Amina Ali
Author:
Evon Poon
Author:
Mohamed Zaki Khelifa
Author:
Guowei Yang
Author:
Catarina Jones
Author:
Rosalia Moreddu
Author:
Nan Jiang
Author:
Savas Tasoglu
Author:
Louis Chesler
Author:
Ali K. Yetisen
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics